Clinuvel compared to Imugene, page-54

One major difference between Neuren and Clinuvel is that Neuren licenced out their drug prior to phase 3 whilst Clinuvel has taken on responsibility for the whole roll out of Scenesse. Neuren has been free to focus on their next drug in multiple phase 2 studies while their partner is better resourced for distribution and incentivised to get it out to patients quickly. Obviously then Neuren gets less of the revenues but the milestones in the deal have meant Neuren in well under a year since approval already have cash over $200 million and their expenses for the first drug are all taken care of. I'm not sure how this would have worked for Clinuvel with EPP and Scenesse but the tendency for Wolgen to want to control everything and keep everything under lock and key doesn't look like the best strategy so far.